Factor Bioscience develops advanced cell engineering therapies using its proprietary RNA-based gene-editing platform. Factor's pipeline includes autologous, allogeneic, iPSC-derived, and in-vivo CAR-T and myeloid/macrophage programs for oncology and immunology indications. Factor is planning a BLA for the first dual CAR-T targeting rrMM with extramedullary disease in 2027 and is actively seeking to partner this and other programs.